MedTrace Logo

Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)

NCT04921553 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2021-08-02

No results posted yet for this study

Summary

This registry will make it possible to describe real life management of patients with rare actionable fusions and to better understand these cancers. In addition of clinical data from the medical files, a quality of life questionnaire (QLQ-C30) will be complete at inclusion, at each new treatment and then every 6 months. The patients will be followed for a period of at least 2 years after the inclusion.

This TRacKING registry is a European collaborative tool to improve the management of patients with actionable fusions, by sharing of data from rare tumor indications.

Conditions

  • Cancer
  • Cancer Metastatic
  • NTRK Gene Fusion Overexpression
  • NTRK Family Gene Mutation
  • ATIC-ALK Fusion Protein Expression
  • ALK Fusion Protein Expression
  • BCR-FGFR1 Fusion Protein Expression
  • ROS1 Gene Translocation
  • COL1A1-PDGFB Fusion Protein Expression
  • RET Gene Translocation
  • Gene Fusion
  • ROS Gene Translocation
  • BRAF Gene Rearrangement
  • FGFR2 Gene Translocation
  • FGFR3 Gene Translocation
  • NTRK1 Gene Translocation

Interventions

OTHER

Data collection and quality of life questionnaire

* Data collection from the medical file * Quality of life questionnaire (QLQC30) at inclusion, at each change of treatment and then every 6 months

Sponsors & Collaborators

  • Centre Leon Berard

    lead OTHER

Principal Investigators

  • Jean-Yves BLAY, Pr · Centre Leon Berard

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-22
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • Austria
  • Czechia
  • Denmark
  • France
  • Germany
  • Italy
  • Netherlands
  • Poland
  • Slovenia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04921553 on ClinicalTrials.gov